BioPharma Drive: Drug Pricing
NOVEMBER 1, 2024
The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm GLP-1s aren't a "silver bullet" for MASH, one analyst argued.
Drugs.com
NOVEMBER 1, 2024
FRIDAY, Nov. 1, 2024 -- The GLP-1 drug semaglutide can help obese people manage debilitating knee arthritis, a new trial has found.People who received weekly injections of semaglutide -- the active agent in the diabetes drug Ozempic and the.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Science Daily: Pharmacology News
NOVEMBER 1, 2024
Biomedical engineers have invented a 3D printing system, or bioprinter, capable of fabricating structures that closely mimic the diverse tissues in the human body, from soft brain tissue to harder materials like cartilage and bone.
Drugs.com
NOVEMBER 1, 2024
FRIDAY, Nov. 1, 2024 -- Sleep apnea appears to increase a person's odds of developing dementia, a new study finds.The effect seems stronger among women compared to men, noted a research team from the University of Michigan. Luckily, there are.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Science Daily: Pharmacology News
NOVEMBER 1, 2024
Teams of astronomers used the combined power of NASA's Hubble and James Webb space telescopes to revisit the legendary Vega disk.
Drugs.com
NOVEMBER 1, 2024
FRIDAY, Nov. 1, 2024 -- Yoga can help ease chronic low back pain, even if the classes are conducted online, a new study shows. Guidelines recommend using physical therapy or yoga to treat lower back pain before moving on to painkillers, but it can.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drug Channels
NOVEMBER 1, 2024
Today’s guest post comes from Kimberley Chiang, Vice President of Biopharma Commercial Solutions at CoverMyMeds Kimberley highlghts the crucial roles of field reimbursement managers in removing access and reimbursement barriers. She then identifies the keys to successful implementation of field reimbursement services. To learn more, register for CoverMyMeds' November 13, 2024, webinar: Specialty Therapies & Field Reimbursement Services: Driving Better Outcomes for Brands and Patients.
Covalent Modifiers
NOVEMBER 1, 2024
Yasir S. Raouf and Carlos Moreno-Yruela JACS Au , 2024 DOI: 10.1021/jacsau.4c00828 The dysregulated post-translational modification of proteins is an established hallmark of human disease. Through Zn2+-dependent hydrolysis of acyl-lysine modifications, histone deacetylases (HDACs) are key regulators of disease-implicated signaling pathways and tractable drug targets in the clinic.
BioPharma Drive: Drug Pricing
NOVEMBER 1, 2024
Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck’s Longboard buyout and PTC continued a quixotic quest.
Drugs.com
NOVEMBER 1, 2024
FRIDAY, Nov. 1, 2024 -- Seniors who’ve had a heart attack should probably delay any elective surgeries for three to six months, a new study advises.People aged 67 and older face double to triple the risk of life-threatening complications -- like a s.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Perficient: Drug Development
NOVEMBER 1, 2024
Remember the days when robots and artificial intelligence (AI) were confined to the realms of science fiction? Fast forward to today, and AI in healthcare is rapidly transforming how we diagnose, treat, and care for patients. From intelligent algorithms diagnosing diseases faster than the human eye, to virtual health assistants providing round-the-clock support, AI is revolutionizing the healthcare industry.
Broad Institute
NOVEMBER 1, 2024
Jacques Deguine By Maria Nemchuk November 1, 2024 Jacques Deguine, Ph.D. Scientific Director of the Immunology Program; Group Leader, Immunoprofiling Innovation Lab at the Center for Integrated Study of Infectious Diseases Jacques Deguine is scientific director of the Immunology Program at the Broad Institute of MIT and Harvard, under the leadership of Ramnik Xavier.
KIF1A
NOVEMBER 1, 2024
Welcome to this month’s edition of the KIF1A.ORG newsletter! We have some exciting news to share with you so read on and stay informed! SAVE the DATE! 2025 KAND Family & Scientific Engagement Conference We’re excited to announce the official dates for our 2025 KAND Conference! Mark your calendars for July 25-26, 2025, and plan to join us in Boston.
Perficient: Drug Development
NOVEMBER 1, 2024
As part of our commitment to supporting children in need, Perficient Hyderabad recently embraced an opportunity to make a meaningful impact at the Sankalp Foundation during Hunger Action Month(HAM). This initiative was driven by our Perficient Employee Resource Group (ERG) , focused on community service and social responsibility, and aimed at transforming lives through joy and engagement.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drugs.com
NOVEMBER 1, 2024
FRIDAY, Nov. 1, 2024 -- Are people with autism less able to "read" the nefarious intent of criminals, leaving them more vulnerable to scams or coercion into criminal activity?It's been a common notion among trial lawyers, the Australian researchers.
Perficient: Drug Development
NOVEMBER 1, 2024
Artificial intelligence (AI) is poised to affect every aspect of the world economy and play a significant role in the global financial system, leading financial regulators around the world to take various steps to address the impact of AI on their areas of responsibility. The economic risks of AI to the financial systems include everything from the potential for consumer and institutional fraud to algorithmic discrimination and AI-enabled cybersecurity risks.
Drugs.com
NOVEMBER 1, 2024
FRIDAY, Nov. 1, 2024 -- Cirrhosis, hepatitis infection and other causes can trigger liver fibrosis -- a potentially lethal stiffening of tissue that, once begun, is irreversible. For many patients, a liver transplant is their only hope. However.
Drug Target Review
NOVEMBER 1, 2024
Strategies for the synthesis and development of complex active pharmaceutical ingredients While the prevalence of biologics has grown within the pharmaceutical sector over recent decades, small molecules remain important and can offer significant advantages. Most are taken orally by patients and are bioavailable to target both extracellular components, such as surface receptors, and intracellular proteins by easily permeating the cell membrane.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drugs.com
NOVEMBER 1, 2024
FRIDAY, Nov. 1, 2024 -- Folks with more money and better education are at less risk for developing dementia as they grow older, a new study shows.People with advantaged backgrounds are less likely to develop mild cognitive impairment, and to.
Alta Sciences
NOVEMBER 1, 2024
ISSUE NO. 42 — Managing The Complexities of Glucagon-Like Peptide-1 Receptor Agonist Drug Development tchichekian Fri, 11/01/2024 - 14:25 Publication The-Altascientist-issue-42-GLP-1-Drug-Development.
Drugs.com
NOVEMBER 1, 2024
FRIDAY, Nov. 1, 2024 -- Smokers diagnosed with cancer often shrug and keep lighting up, figuring a few more butts won’t make much difference.They’re very mistaken, a new study finds.Smokers are 22% to 26% less likely to die if they quit following a.
Codon
NOVEMBER 1, 2024
Dario Amodei, the CEO of Anthropic , recently published an essay called “ Machines of Loving Grace.” It sketches out his vision for how AI could radically transform neuroscience, economics, diplomacy, and the meaning of work. Amodei also imagines the ways AI could accelerate biological research and yield miraculous cures in the 21st century; everything from the prevention and treatment of nearly all infectious and inherited diseases to the elimination of most cancers. “Biology
Drugs.com
NOVEMBER 1, 2024
FRIDAY, Nov. 1, 2024 -- Hillary Fisher thinks receiving weight-loss surgery as a teenager put her on the path to a better life.Fisher is one of 260 teens who participated in a long-term study which recently concluded that weight-loss surgery can.
Expert insights. Personalized for you.
109 
Let's personalize your content